Dr. Robert J. Fallon

Hematology | Oncology
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 
Riley Hospital For Children At Indiana University Health
705 Riley Hospital Dr, 
Indianapolis, IN 

Overview

Robert Fallon is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana.

Her clinical expertise encompasses Venous Thromboembolism (VTE), Clear Cell Sarcoma, Alveolar Soft Part Sarcoma, and Acute Lymphoblastic Leukemia (ALL).

She is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 35 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in IN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Riley Hospital for Children at Indiana University Health
705 Riley Hospital Dr, Indianapolis, IN 46202

Additional Areas of Focus

Dr. Fallon has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

35 Clinical Trials

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Completed
Publish Date: July 31, 2026
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
View 9 Less Clinical Trials

4 Total Publications

SUCCESSFUL TREATMENT OF A SOLITARY SKULL METASTASIS IN A CHILD WITH WILMS' TUMOR.
SUCCESSFUL TREATMENT OF A SOLITARY SKULL METASTASIS IN A CHILD WITH WILMS' TUMOR.
Journal: Journal of pediatric surgery case reports
Published: November 14, 2017
Similar Doctors
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy D. Shapiro
Hematology | Oncology
Referral may be required

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (9.0 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis. Dr. Shapiro is currently accepting new patients.

Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Expertise in
29
conditions
Dr. Daniel A. Rushing
Hematology | Oncology
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (0.2 miles away)
317-948-8310
Languages Spoken:
English
See accepted insurances

Daniel Rushing is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rushing is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, and Bone Tumor.

Expertise in
7
conditions
Dr. Steven D. Rhodes
Hematology | Oncology
Expertise in
7
conditions
Dr. Steven D. Rhodes
Hematology | Oncology
Referral may be required

Riley Hospital For Children At Indiana University Health

705 Riley Hospital Dr, 
Indianapolis, IN 
 (0.1 miles away)
317-944-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Rhodes is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Rhodes is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, RASopathies, and Malignant Peripheral Nerve Sheath Tumor. Dr. Rhodes is currently accepting new patients.

Frequently Asked Questions about Dr. Robert J. Fallon

How do I make an appointment with Dr. Robert J. Fallon?

You can book an appointment with Dr. Robert J. Fallon by calling their office at 317-944-2143. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert J. Fallon a top-rated expert for Venous Thromboembolism (VTE)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert J. Fallon is classified as an Experienced expert for Venous Thromboembolism (VTE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert J. Fallon specialize in?

While Dr. Robert J. Fallon is a Hematology, they have specific expertise in Venous Thromboembolism (VTE), Clear Cell Sarcoma, and Alveolar Soft Part Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Robert J. Fallon participate in research or clinical trials?

Yes. Dr. Robert J. Fallon has published 4 articles and abstracts on conditions like Venous Thromboembolism (VTE). You can view a list of Dr. Robert J. Fallon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fallon's expertise for a condition
ConditionClose
        View All 21 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile